<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>HYOSCYAMINE SULFATE- hyoscyamine sulfateÂ tabletÂ </strong><br>County Line Pharmaceuticals, LLC<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>Hyoscyamine Sulfate Tablets, USP, 0.125 mg<br>PI-9326<br>Rev 02/09  Â Â Â Rx Only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_b25bc78f-3452-4026-a3a5-0beca242a211"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Hyoscyamine Sulfate Tablets, USP contain 0.125 mg hyoscyamine sulfate formulated for oral administration. </p>
<p>Hyoscyamine sulfate is one of the principal anticholinergic/antispasmodic components of belladonna alkaloids. The empirical formula is (C<span class="Sub">17</span>H<span class="Sub">23</span>NO<span class="Sub">3</span>)<span class="Sub">2</span>â€¢H<span class="Sub">2</span>SO<span class="Sub">4</span>â€¢2H<span class="Sub">2</span>O and the molecular weight is 712.85. Chemically, it is benzeneacetic acid, Î±-(hydroxymethyl)-, 8-methyl-8-azabicyclo [3.2.1] oct-3-yl ester, [3(S)-endo]-, sulfate (2:1), dihydrate with the following structure: </p>
<div class="Figure"><img alt="Molecular Structure of Hyoscyamine sulfate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=480d688d-2103-443c-90cc-feb861bdce13&amp;name=480d688d-2103-443c-90cc-feb861bdce13-01.jpg"></div>
<p>Each tablet also contains as inactive ingredients: Colloidal silicon dioxide, crospovidone, magnesium stearate and microcrystalline cellulose. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_1b1589b2-cd8c-4540-8f96-229410ec9292"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Hyoscyamine sulfate inhibits specifically the actions of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of the smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node and the exocrine glands. At therapeutic doses, it is completely devoid of any action on the autonomic ganglia. Hyoscyamine sulfate inhibits gastrointestinal propulsive motility and decreases gastric acid secretion. Hyoscyamine sulfate also controls excessive pharyngeal, tracheal and bronchial secretions. </p>
<p>Hyoscyamine sulfate is absorbed totally and completely by oral administration. Once absorbed, hyoscyamine sulfate disappears rapidly from the blood and is distributed throughout the entire body. The half-life of hyoscyamine sulfate is 2 to 3 1/2 hours. Hyoscyamine sulfate is partly hydrolyzed to tropic acid and tropine but the majority of the drug is excreted in the urine unchanged within the first 12 hours. Only traces of this drug are found in breast milk. Hyoscyamine sulfate passes the blood brain barrier and the placental barrier. </p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_3ce8ec7a-129e-497f-b052-d4e939214717"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Hyoscyamine Sulfate Tablets, USP are effective as adjunctive therapy in the treatment of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>. They can also be used to control gastric secretions, visceral spasm and hypermotility in spastic <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, spastic bladder, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, pylorospasm and associated <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>. May be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span> and acute <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>. For use as adjunctive therapy in the treatment of <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> (<span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable colon</span>, <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">spastic colon</span>, <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">mucous colitis</span>) and functional <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>. Also used as adjunctive therapy in the treatment of <span class="product-label-link" type="condition" conceptid="199075" conceptname="Neurogenic bladder">neurogenic bladder</span> and neurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). Hyoscyamine Sulfate Tablets, USP are indicated along with morphine or other narcotics in symptomatic relief of biliary and <span class="product-label-link" type="condition" conceptid="201690" conceptname="Renal colic">renal colic</span>; as a â€œdrying agentâ€? in the relief of symptoms of acute <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>; in the therapy of <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> to reduce <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span> and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> and to control associated <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">sialorrhea</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>. May be used in the therapy of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> by anticholinesterase agents. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_ba6decc0-5ccd-44e2-b383-4d00c766a1f1"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>; <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">obstructive uropathy</span> (for example, <span class="product-label-link" type="condition" conceptid="433813" conceptname="Bladder neck obstruction">bladder neck obstruction</span> due to <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis); <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, intestinal atony of elderly or debilitated patients; unstable cardiovascular status in acute <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>; severe <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>; toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span> complicating <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>; <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_83e97e56-0c9c-4719-88ba-46ea74793962"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In the presence of high environmental temperature, <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat prostration</span> can occur with drug use (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span> due to decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>). <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> may be an early symptom of incomplete <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, especially in patients with ileostomy or colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful. Like other anticholinergic agents, hyoscyamine sulfate may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery or to perform hazardous work while taking this drug. </p>
<p><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> has been reported in sensitive individuals given anticholinergic drugs including hyoscyamine sulfate. CNS signs and symptoms include <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, short-term <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, decreased <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and mannerisms and <span class="product-label-link" type="condition" conceptid="4154304" conceptname="Inappropriate affect">inappropriate affect</span>. These CNS signs and symptoms usually resolve within 12 to 48 hours after discontinuation of the drug. </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_737d3b27-829e-41b6-8c6a-031423032df7"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_62d117e7-7b30-4a57-9f8f-c773e743640e"></a><a name="section-6.1"></a><p></p>
<h2><span class="Italics">General: </span></h2>
<p class="First">Use with caution in patients with: <span class="product-label-link" type="condition" conceptid="4080146" conceptname="Autonomic neuropathy">autonomic neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, coronary heart disease, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Investigate any <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> before giving any anticholinergic drugs since they may increase the heart rate. Use with caution in patients with <span class="product-label-link" type="condition" conceptid="4224004" conceptname="Hiatal hernia">hiatal hernia</span> associated with <span class="product-label-link" type="condition" conceptid="30437" conceptname="Gastro-esophageal reflux disease with esophagitis">reflux esophagitis</span>. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_17e0798c-1a2e-45b3-a637-e106438bfde1"></a><a name="section-6.2"></a><p></p>
<h2><span class="Italics">Information for Patients: </span></h2>
<p class="First">Like other anticholinergic agents, hyoscyamine sulfate may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery or to perform hazardous work while taking this drug. </p>
<p>Use of hyoscyamine sulfate may decrease <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> resulting in <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat prostration</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>; febrile patients or those who may be exposed to elevated environmental temperatures should use caution. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_id_723cfa75-0929-480f-88d6-6911509e083e"></a><a name="section-6.3"></a><p></p>
<h2><span class="Italics">Drug Interactions: </span></h2>
<p class="First">Additive adverse effects resulting from cholinergic blockade may occur when hyoscyamine sulfate is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines. </p>
<p>Antacids may interfere with the absorption of hyoscyamine sulfate. Administer Hyoscyamine Sulfate Tablets, USP before meals; antacids after meals. </p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_4afdfcab-08da-4b7b-96f9-d5a1039125d1"></a><a name="section-6.4"></a><p></p>
<h2><span class="Italics">Carcinogenesis, Mutagenesis, Impairment of Fertility: </span></h2>
<p class="First">No long-term studies in animals have been performed to determine the carcinogenic, mutagenic or impairment of fertility potential of hyoscyamine sulfate; however, 40 years of marketing experience with hyoscyamine sulfate shows no demonstrable evidence of a problem. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_C_id_b0882907-2d7b-44a8-95f4-595a4890ee12"></a><a name="section-6.5"></a><p></p>
<h2><span class="Italics">Pregnancy-Pregnancy Category C: </span></h2>
<p class="First">Animal reproduction studies have not been conducted with hyoscyamine sulfate. It is also not known whether hyoscyamine sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Hyoscyamine Sulfate Tablets, USP should be given to a pregnant woman only if clearly needed. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_f9ab614d-3e4e-4955-85b2-2795b7db221b"></a><a name="section-6.6"></a><p></p>
<h2><span class="Italics">Nursing Mothers: </span></h2>
<p class="First">Hyoscyamine sulfate is excreted in human milk. Caution should be exercised when Hyoscyamine Sulfate Tablets, USP are administered to a nursing woman. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_075d0521-47b2-4ee2-8237-a7c290265859"></a><a name="section-6.7"></a><p></p>
<h2><span class="Italics">Geriatric Use: </span></h2>
<p class="First">Reported clinical experience has not identified differences in safety between patients aged 65 and over and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. </p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_577589be-1c53-4620-bbd7-4522ff1f8981"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions have been reported for hyoscyamine sulfate and for pharmacologically similar drugs with anticholinergic/antispasmodic action. Adverse reactions may include dryness of the mouth; <span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitancy</span> and retention; <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>; <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>; <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>; <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span>; increased ocular <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>; <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">loss of taste</span>; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>; <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>; suppression of lactation; <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>; <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">bloated feeling</span>; <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>; <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> or drug idiosyncrasies; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and other dermal manifestations; <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>; speech disturbance; some degree of <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span> and/or <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> (especially in elderly persons); short-term <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>; <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>; and decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_5208f9f9-a3f8-49c7-8d40-6655707212ce"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The signs and symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">hot dry skin</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, dryness of the mouth, difficulty in swallowing and CNS stimulation. </p>
<p>Measures to be taken are immediate lavage of the stomach and injection of physostigmine 0.5 to 2 mg intravenously and repeated as necessary up to a total of 5 mg. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> may be treated symptomatically (tepid water sponge baths, hypothermic blanket). <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Excitement</span> to a degree which demands attention may be managed with sodium thiopental 2% solution given slowly intravenously or chloral hydrate (100-200 mL of a 2% solution) by rectal infusion. In the event of progression of the curare-like effect to <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of the respiratory muscles, artificial respiration should be instituted and maintained until effective respiratory action returns. </p>
<p>In rats, the LD50 for hyoscyamine is 375 mg/kg. Hyoscyamine sulfate is dialyzable. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_cfcaaa5e-59cb-4dcb-801e-5793ce5e38d6"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Dosage may be adjusted according to the conditions and severity of symptoms. </p>
<p><span class="Italics">Adults and pediatric patients 12 years of age and older:</span> 1 to 2 tablets every four hours or as needed. Do not exceed 12 tablets in 24 hours. </p>
<p><span class="Italics">Pediatric patients 2 to under 12 years of age: </span>1/2 to 1 tablet every four hours or as needed. Do not exceed 6 tablets in 24 hours. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_858ad9d8-cb75-4bff-86ae-4986e14faef8"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Hyoscyamine Sulfate Tablets, USP, 0.125 mg are white, round, biconvex tablets debossed with â€œCLâ€? on one side and â€œ13â€? on the other. </p>
<p>Bottles of 100<br>NDC 43199-013-01 </p>
<p>Store at controlled room temperature 20Â°-25Â°C (68Â°-77Â°F); excursion permitted to 15Â°-30Â°C (59Â°-86Â°F). Please refer to current USP. </p>
<p>Dispense in tight, light-resistant containers as defined in USP/NF with a child-resistant closure. </p>
<p>KEEP OUT OF REACH OF CHILDREN </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b883b686-bd01-45e8-8b3f-55824b7cf06a"></a><a name="section-11"></a><p></p>
<p class="First">Manufactured for: </p>
<p>County Line Pharmaceuticals, LLC </p>
<p>Brookfield, WI 53005 </p>
<p>For inquiries call toll free 1-866-207-5636. </p>
<p>PI-9326<br>Rev 02/09 </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_784aa861-b88d-4d48-8505-bfaab0dc077c"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Hyoscyamine Sulfate Tablets, USP label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=480d688d-2103-443c-90cc-feb861bdce13&amp;name=480d688d-2103-443c-90cc-feb861bdce13-02.jpg"></div>
<p class="First"><span class="Bold">NDCÂ 43199-013-01</span></p>
<p><span class="Bold">100Â Tablets</span></p>
<p><span class="Bold">Hyoscyamine Sulfate Tablets, USP</span></p>
<p><span class="Bold">0.125 mg</span></p>
<p><span class="Bold">RxÂ Only</span></p>
<p>EachÂ tabletÂ containsÂ 0.125Â mgÂ hyoscyamineÂ sulfate,Â USP.</p>
<p><span class="Bold">USUALÂ DOSAGE:<br></span>SeeÂ packageÂ insertÂ forÂ fullÂ prescribingÂ information.</p>
<p>Dispense in tight, light-resistant containers as defined in USP/NF with a child-resistant closure.</p>
<p>Store at controlled room temperature 20Â°-25Â°C (68Â°-77Â°F); excursions permitted to 15Â°-30Â°C (59Â°-86Â°F). Please refer to current USP. </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HYOSCYAMINE SULFATEÂ 		
					</strong><br><span class="contentTableReg">hyoscyamine sulfate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43199-013</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYOSCYAMINE SULFATE</strong> (HYOSCYAMINE) </td>
<td class="formItem">HYOSCYAMINE SULFATE</td>
<td class="formItem">0.125Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CL;13</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:43199-013-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">11/05/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>County Line Pharmaceuticals, LLC
							(015585278)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANIP Acquistion Company</td>
<td class="formItem"></td>
<td class="formItem">831049809</td>
<td class="formItem">ANALYSIS, MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>480d688d-2103-443c-90cc-feb861bdce13</div>
<div>Set id: 480d688d-2103-443c-90cc-feb861bdce13</div>
<div>Version: 1</div>
<div>Effective Time: 20100111</div>
</div>
</div>Â <div class="DistributorName">County Line Pharmaceuticals, LLC</div></p>
</body></html>
